Search clinical trials for: PREVNAR 13®

Total 14335 results

St. Antonius Hospital

Completed

Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status (CAPolista)

Pneumonia | Immune Response | Streptococcus Pneumoniae

Netherlands
Murdoch Childrens Research Institute
National Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaborators

Completed

Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam

Pneumococcal Vaccines

Vietnam
GlaxoSmithKline

Completed

A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays

Meningococcal

Canada
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) (PNEU-AGE)

Pneumococcal Infections

Taiwan, United States, Canada, Japan, Spain
AbbVie

Completed

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis (BALANCE-EXTEND)

Rheumatoid Arthritis

United States, Belgium, Bulgaria, Chile, Czechia, Hungary, Israel, Latvia, Mexico, New Zealand, Poland, Puerto Rico, Russian Federation, Slovakia, South Africa, Spain, Ukraine, United Kingdom
University of Oxford

Completed

A Study of the Interaction Between BCG And MenC Immunisation: BAM (BAM)

Immune Response | BCG Infection | Reaction - Vaccine

United Kingdom
GlaxoSmithKline

Completed

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

Infections, Streptococcal

United States
GlaxoSmithKline

Completed

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States
London School of Hygiene and Tropical Medicine
University College, London; Bill and Melinda Gates Foundation; Wellcome Trust; KEMRI-Wellcome... and other collaborators

Active, not recruiting

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (FPCV)

Pneumococcal Infection | Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection Against

Kenya
Canadian Immunization Research Network

Completed

Vaccinating Children After Chemotherapy

Acute Lymphoblastic Leukemia

Canada
Wuhan BravoVax Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention; Liaoning Chengda...

Recruiting

Phase I Clinical Trial of a Candidate PCV13 in Healthy People

Pneumococcal Infections

China
Papua New Guinea Institute of Medical Research
The University of Western Australia

Unknown

Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children (PCV1103)

Pneumonia | Sepsis | Meningitis | Otitis Media | Bacteraemia

Papua New Guinea
MCM Vaccines B.V.
Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi Company

Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PNEU-PED-EU-2)

Pneumococcal Infections

Denmark, Finland, Italy, Norway, Sweden
Merck Sharp & Dohme LLC

Completed

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Pneumococcal Infections
Jiangsu Province Centers for Disease Control and...
Beijing Minhai Biotechnology Co., Ltd

Completed

A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Pneumonia

China
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

Pneumococcal Infections
Michigan State University
Pfizer

Completed

Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

End Stage Renal Disease

United States
University Hospital Southampton NHS Foundation...
Solent NHS Trust

Unknown

Paediatric Post Pneumococcal Conjugate Vaccine Nasopharyngeal Carriage Study

Pneumococcal Conjugate Vaccine | S. Pneumoniae

United Kingdom
MCM Vaccines B.V.

Completed

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
GlaxoSmithKline

Completed

Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Mexico
GlaxoSmithKline

Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Germany, France, Canada
GlaxoSmithKline

Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
Lakehead University

Completed

The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13

Chronic Kidney Diseases

Canada
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) (PNEU-PLAN)

Pneumococcal Infections

Finland, Malaysia, Poland, Russian Federation, Thailand
Pfizer

Completed

Prevenar13 Post Market Surveillance

Healthy

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
University of British Columbia
Canadian Institutes of Health Research (CIHR); University of Calgary; Alberta... and other collaborators

Completed

CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study

Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection Against

Canada
CanSino Biologics Inc.
Henan Center for Disease Control and Prevention

Completed

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

Pneumococcal Infections | Bacterial Infections | Streptococcal Infections

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Pneumococcal Infections

United States, Brazil, Colombia, Dominican Republic, Greece, Italy, Panama
Merck Sharp & Dohme LLC

Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (PNEU-TRUE)

Pneumococcal Infections | Pneumonia, Pneumococcal

United States, Australia, Chile, Denmark, Finland, United Kingdom
Nuron Biotech Inc.

Unknown

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

Infectious Disease

United States
Affinivax, Inc.

Completed

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Healthy Volunteers | Pneumococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Virus Diseases | Bacterial Infections
Pfizer

Completed

Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

Pneumococcal Disease

Philippines
GlaxoSmithKline
Affinivax, Inc.

Recruiting

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants

Pneumococcal Infections | Pneumonia, Pneumococcal | Pneumonia, Bacterial

United States, Puerto Rico
Medical University of South Carolina

Completed

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

Aging | HIV Lipodystrophy

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)

Pneumococcal Infections

Japan
Sinovac Research and Development Co., Ltd.

Recruiting

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infectious Disease

China
VA Eastern Colorado Health Care System

Recruiting

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

HIV Infections | HIV/AIDS | Human Immunodeficiency Virus | HIV-1-infection

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (PCV13)

Multiple Myeloma

United States
Pfizer

Terminated

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

Pneumococcal Infections

United States
University of California, Los Angeles

Active, not recruiting

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)

Infection in Solid Organ Transplant Recipients

United States
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Vaccine Responses in Patients With B Cell Malignancies

Lymphoma

United States
GlaxoSmithKline
Affinivax, Inc.

Completed

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Pneumonia, Bacterial | Healthy Volunteers | Pneumococcal Disease

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Unknown

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Pneumococcal Infections | HIV | Pneumococcal Vaccines

United States
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Pneumococcal Infections

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

France, Poland

Search clinical trials for: PREVNAR 13®

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations